Please login to the form below

Not currently logged in
Email:
Password:

Tourette's syndrome

This page shows the latest Tourette's syndrome news and features for those working in and with pharma, biotech and healthcare.

Neurocrine bags FDA approval for first tardive dyskinesia drug

Neurocrine bags FDA approval for first tardive dyskinesia drug

Neurocrine says it is also expecting to report results for a trial of valbenazine in children with Tourette's syndrome next month, although an earlier study in adults failed to show ... If positive, Neurocrine is hoping to start a phase III trial in

Latest news

  • FDA sets August review date for Teva's movement disorder drug FDA sets August review date for Teva's movement disorder drug

    FDA sets August review date for Teva's movement disorder drug. Could be first approved treatment for tardive dyskinesia. ... Both companies are also exploring the use of their respective drugs to prevent tics associated with Tourette's syndrome.

  • FDA turns down Teva's Huntington's disease drug FDA turns down Teva's Huntington's disease drug

    FDA turns down Teva's Huntington's disease drug. Has requested further analysis on certain metabolites of the chorea candidate. ... and tics associated with Tourette's syndrome.

  • Neurocrine plans movement disorder drug filing in 2016 Neurocrine plans movement disorder drug filing in 2016

    Analysts at Nomura recently predicted that NBI-98854 could eventually become a $1.5bn product, even without a possible follow-up indication in Tourette's syndrome - and the announcement of the ... Neurocrine expects to complete its first phase Ib trial

  • Teva drug shows promise in movement disorder Teva drug shows promise in movement disorder

    in the US," said the trial's principal investigator Hubert Fernandez of the Cleveland Clinic. ... It also has late-stage trials ongoing in chorea associated with Tourette's syndrome.

  • FDA starts review of Lundbeck’s antipsychotic aripiprazole

    FDA starts review of Lundbeck’ s antipsychotic aripiprazole. Major milestone reached in CNS alliance between Danish pharma company and Otsuka. ... Otsuka is also developing a once-weekly oral formulation of aripiprazole which recently started phase III

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics